Clinical Trial Update: A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating sintilimab plus ramucirumab as first-line treatment for gastric/gastroesophageal junction adenocarcinoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Ramucirumab (ramucirumab)
• Sintilimab (sintilimab)

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Gastric Adenocarcinoma | Phase 3 | Status: TERMINATED